Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials
Joint Authors
Huang, Jing
Xiong, Shuyuan
Ding, Shenglan
Cheng, Qingfeng
Liu, Zhiping
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-14
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Aims.
To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods.
Methods.
We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020.
A total of six studies involving 4120 patients were included.
Results.
Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of genital mycotic infections (GMIs) at 26 weeks (p<0.0001 and p<0.0001, respectively), 52 weeks (p<0.00001 and p<0.0001, respectively), and 104 weeks (p<0.00001 and p<0.0001, respectively).
Moreover, females had a higher risk of GMIs than males in the 15 mg group at 26 weeks (p=0.0008), 52 weeks (p<0.0001), and 104 weeks (p=0.02).
At 104 weeks, 15 mg and 5 mg of ertugliflozin showed beneficial effects on symptomatic hypoglycemia (p<0.00001 and p=0.004, respectively) compared with the effects observed in the control group.
Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of drug-related adverse events at 26 weeks (p=0.002 and p=0.002, respectively); 15 mg of ertugliflozin was associated with a higher risk of discontinuation related to adverse events at 104 weeks (p=0.03).
No significant differences were found in the remaining safety outcomes.
Conclusion.
This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.
American Psychological Association (APA)
Huang, Jing& Xiong, Shuyuan& Ding, Shenglan& Cheng, Qingfeng& Liu, Zhiping. 2020. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research،Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
Modern Language Association (MLA)
Huang, Jing…[et al.]. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research No. 2020 (2020), pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
American Medical Association (AMA)
Huang, Jing& Xiong, Shuyuan& Ding, Shenglan& Cheng, Qingfeng& Liu, Zhiping. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research. 2020. Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1183589